On average, Zepbound (tirzepatide) produced more weight loss in trials than Wegovy (semaglutide) — around 20% of body weight at higher doses versus about 15%. Zepbound is a dual GIP/GLP-1 agonist from Eli Lilly; Wegovy is a GLP-1 agonist from Novo Nordisk. Both are once-weekly injections approved for chronic weight management. But "wins" oversimplifies it: tolerability, cost, insurance coverage and how your own body responds all shape the real-world result. This is education, not a recommendation — the choice is made with a clinician.
Key takeaways
- Zepbound = tirzepatide (dual GIP/GLP-1, Eli Lilly); Wegovy = semaglutide (GLP-1, Novo Nordisk).
- Average trial weight loss favors tirzepatide (~20%) over semaglutide 2.4 mg (~15%) — but these are averages, not guarantees.
- Extra approvals differ: Zepbound is also approved for obstructive sleep apnea with obesity; Wegovy is also approved to reduce cardiovascular risk.
- Both share the GLP-1 GI side-effect profile. "Best" depends on tolerability, coverage and cost, not just the headline number.
What's the difference between Zepbound and Wegovy?
The core difference is the molecule. Zepbound is tirzepatide, a dual agonist that activates two gut-hormone receptors — GIP and GLP-1. Wegovy is semaglutide, a GLP-1 receptor agonist that acts on one. Both slow gastric emptying, reduce appetite and quiet cravings, but tirzepatide's second target (GIP) is the structural reason many researchers point to for its higher average weight loss.
Both are once-weekly subcutaneous injections, both are titrated up slowly from a low starting dose, and both are FDA-approved specifically for chronic weight management in adults who meet BMI criteria. In other words, they're direct competitors for the same job — which is exactly why the comparison is worth making carefully.
Zepbound vs Wegovy: side-by-side
| Zepbound | Wegovy | |
|---|---|---|
| Molecule | Tirzepatide (dual GIP/GLP-1 agonist) | Semaglutide (GLP-1 agonist) |
| Maker | Eli Lilly | Novo Nordisk |
| Approved uses | Chronic weight management; obstructive sleep apnea with obesity | Chronic weight management; reducing cardiovascular risk |
| Form & frequency | Once-weekly injection | Once-weekly injection |
| Average weight loss (trials) | ~20% at higher doses (SURMOUNT) | ~15% at 2.4 mg (STEP) |
| Maximum dose | Up to 15 mg | Up to 2.4 mg (standard weight-management dose) |
| Cost / coverage | Varies widely; verify current details | Varies widely; verify current details |
The maximum-dose numbers aren't directly comparable — 15 mg of tirzepatide and 2.4 mg of semaglutide are simply different molecules dosed on different scales. What matters is the outcome each dose produces, not the milligram figure.
Which causes more weight loss?
In the pivotal trials, tirzepatide (Zepbound) averaged roughly 20% of body weight lost at its higher doses, while semaglutide 2.4 mg (Wegovy) averaged about 15% in the STEP program. On paper, that's a meaningful edge for tirzepatide.
But two caveats keep this honest. First, these figures come from separate trials with different participants, not one perfect head-to-head weight-loss study — so treat the comparison as directional, not exact. Second, they're averages. Plenty of people on Wegovy lose more than the tirzepatide average, and plenty on Zepbound lose less. Your diet, activity, sleep, starting weight and whether you stay on treatment all move the needle. Our weight-loss overview digs into what drives individual results, and the weight-loss calculator can help you set a realistic personal range.
Side effects and other approvals
Both drugs carry the classic GLP-1 gastrointestinal profile — nausea, constipation, diarrhea and reduced appetite — usually worst when starting or stepping up a dose and easing over time. Our side-effects guide covers management. Because tirzepatide also acts on GIP, some people find their tolerability differs between the two, but there's no universally "gentler" option.
The extra approvals are a genuine differentiator. Zepbound is also FDA-approved for moderate-to-severe obstructive sleep apnea in adults with obesity, which can matter if you have that condition. Wegovy is also approved to reduce the risk of major cardiovascular events in adults with established cardiovascular disease and overweight or obesity. If one of those situations applies to you, it may tip the decision regardless of the weight-loss average.
Which is right for you?
- Chasing the highest average weight loss? Tirzepatide leads on the trial numbers — but confirm you can access and tolerate it.
- Have cardiovascular disease? Wegovy's CV-risk approval may be relevant to your clinician's thinking.
- Have obstructive sleep apnea with obesity? Zepbound's additional approval could matter.
- Cost or coverage is the constraint? Whichever your plan approves for your situation may simply be the practical answer.
None of this is a prescription. Both are effective, both require a clinician, and the right pick is the one that fits your body, your health history and your budget. Compare the whole category in our GLP-1 medications guide.
Frequently asked questions
Is Zepbound or Wegovy better for weight loss?
On average, Zepbound (tirzepatide) produced greater weight loss in trials — roughly 20% of body weight at higher doses — than Wegovy (semaglutide 2.4 mg), which averaged about 15%. But these are trial averages and individuals vary. "Better" also depends on tolerability, insurance coverage and cost, so the right choice is individual and decided with a clinician.
What's the difference between Zepbound and Wegovy?
Zepbound is tirzepatide, made by Eli Lilly, a dual GIP/GLP-1 receptor agonist. Wegovy is semaglutide, made by Novo Nordisk, a GLP-1 receptor agonist. Both are once-weekly injections FDA-approved for chronic weight management, but tirzepatide acts on two gut-hormone receptors while semaglutide acts on one.
Is tirzepatide better than semaglutide?
In weight-management trials, tirzepatide averaged higher weight loss than semaglutide 2.4 mg, and it also outperformed semaglutide in a head-to-head diabetes trial. However, "better" depends on more than the average number — side-effect tolerance, cost, coverage and personal response all matter, and only a clinician can decide what's appropriate for you.
Which causes more weight loss, Zepbound or Wegovy?
In their respective trials, Zepbound (tirzepatide) at higher doses averaged around 20% body-weight loss versus about 15% for Wegovy (semaglutide 2.4 mg). These are averages across large groups; some people lose much more or much less on either drug, and results depend on diet, activity and staying on treatment.
Do Zepbound and Wegovy have different side effects?
Both share the typical GLP-1 gastrointestinal side-effect profile — nausea, constipation, diarrhea and reduced appetite — most common when starting or increasing the dose. Because tirzepatide also acts on the GIP receptor, individual tolerability can differ, but there's no single "gentler" drug for everyone. Discuss side effects with your clinician.
Sources & further reading
- U.S. Food & Drug Administration — prescribing information for Zepbound (tirzepatide) and Wegovy (semaglutide).
- SURMOUNT clinical trial program (tirzepatide) and STEP clinical trial program (semaglutide 2.4 mg) — published weight-management results.
- Eli Lilly and Novo Nordisk — manufacturer product and dosing information.